Kiana Mohammadian

Ms. Kiana Mohammadian

Shiraz University of Medical Sciences, Shīrāz, Fārs, Iran
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2024 in Antioxidants
Verified
Journal Article
Open access
PDF file
Kiana MohammadianKiana Mohammadian
Kiana Mohammadian
FFFatemeh Fakhar
Fatemeh Fakhar
SKshayan keramat
shayan keramat
Agata StanekAgata Stanek
Agata Stanek
Non-alcoholic fatty liver disease (NAFLD) is a global public health problem that causes liver-related morbidity and mortality. It is also an independent risk factor for non-communicable diseases. In 2020, a proposal was made to refer to it as “metabolic dysfunction-associated fatty liver disease (MAFLD)”, with concise diagnostic criteria. Given its widespread occurrence, its treatment is crucial. Increased levels of oxidative stress cause this disease. This review aims to evaluate various studies on antioxidant therapies for patients with MAFLD. A comprehensive search for relevant research was conducted on the PubMed, SCOPUS, and ScienceDirect databases, resulting in the identification of 87 studies that met the inclusion criteria. In total, 31.1% of human studies used natural antioxidants, 53.3% used synthetic antioxidants, and 15.5% used both natural and synthetic antioxidants. In human-based studies, natural antioxidants showed 100% efficacy in the treatment of MAFLD, while synthetic antioxidants showed effective results in only 91% of the investigations. In animal-based research, natural antioxidants were fully effective in the treatment of MAFLD, while synthetic antioxidants demonstrated effectiveness in only 87.8% of the evaluations. In conclusion, antioxidants in their natural form are more helpful for patients with MAFLD, and preserving the correct balance of pro-oxidants and antioxidants is a useful way to monitor antioxidant treatment.

26 February 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
Kiana MohammadianKiana Mohammadian
Kiana Mohammadian
NBNarges Basirian
Narges Basirian
FFFatemeh Fakhar
Fatemeh Fakhar
SKshayan keramat
shayan keramat
Agata StanekAgata Stanek
Agata Stanek
Insulin resistance (IR) promotes a prothrombotic milieu by enhancing platelet hyperactivity, oxidative stress, and endothelial dysfunction, driving both microvascular and macrovascular complications in type 2 diabetes. Our review synthesizes mechanistic evidence showing that insulin-resistant platelets exhibit increased basal activation, elevated sensitivity to agonists, and reduced responsiveness to inhibitory signals, with distinct pro-aggregatory subpopulations amplifying thrombotic risk. Molecular pathways underlying platelet hyperactivation include reactive oxygen species accumulation, advanced glycation end-product signaling, disrupted calcium homeostasis, and impaired nitric oxide/prostacyclin pathways. Clinically, these mechanisms contribute to heightened arterial thrombosis, coronary artery disease, stroke, and microvascular injury, including nephropathy and retinopathy. Nutritional interventions emerge as effective modulators of platelet function and vascular health. Diets such as the Mediterranean, DASH, low-glycemic-index, and plant-based regimens, alongside bioactive compounds—including omega-3 fatty acids, polyphenols, vitamins D, E, C, and minerals like magnesium and zinc—may reduce platelet aggregation, oxidative stress, and systemic inflammation while restoring endothelial function. Clinical and epidemiological evidence demonstrates improvements in flow-mediated dilation, arterial elasticity, and stabilization of atherosclerotic plaques following dietary interventions. Integrating whole-diet strategies with targeted nutrients provides synergistic benefits, suggesting that personalized nutritional approaches can mitigate IR-induced platelet hyperactivity and lower vascular risk. These findings highlight nutrition as a practical, evidence-based adjunct to pharmacotherapy for cardiovascular protection in insulin-resistant populations.

28 November 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
FFFatemeh Fakhar
Fatemeh Fakhar
Kiana MohammadianKiana Mohammadian
Kiana Mohammadian
SKshayan keramat
shayan keramat
Agata StanekAgata Stanek
Agata Stanek
Acute leukemia is a prevalent cancer worldwide and is classified into two distinct forms. Currently, various therapies have been developed for this disease; however, the issues of recurrence, resistance to treatment, and adverse effects require the exploration of novel treatments. Polyphenols, classified into four categories, are secondary metabolites originating from plants that demonstrate diverse metabolic features such as anticancer, anti-inflammatory, and antioxidant activities. Consequently, they have attracted attention for therapeutic and preventive measures. Research indicates that dietary polyphenols can mitigate the disease burden of acute leukemias by influencing the molecular pathways associated with the disease and its inflammatory processes. Furthermore, owing to their antioxidant properties, they can reduce the amounts of reactive oxygen species generated from the disrupted molecular pathways in these malignancies. The therapeutic actions of polyphenols can facilitate disease recovery by interrupting the cell cycle and causing apoptosis by activating pro-apoptotic genes. In conclusion, the intake of dietary polyphenols, due to their convenience and availability, coupled with the positive outcomes associated with their use in conjunction with conventional therapies, may function as an efficient therapeutic and preventive measure for acute leukemia.

4 July 2025 in Cells
Verified
Journal Article
Open access
PDF file
Kiana MohammadianKiana Mohammadian
Kiana Mohammadian
MAMelika Asayesh
Melika Asayesh
FFFatemeh Fakhar
Fatemeh Fakhar
SKshayan keramat
shayan keramat
Agata StanekAgata Stanek
Agata Stanek
Autoimmune diseases (AIDs) are chronic, heterogeneous conditions developing from an aberrant immune response, impacting particular organs or multiple systems. This systematic review attempted to investigate and evaluate the correlation between autoimmune diseases and cardiovascular disease (CVD), emphasizing immunological and pathophysiological mechanisms. A comprehensive search for relevant research was conducted on the PubMed, SCOPUS, and ScienceDirect databases, resulting in the identification of 28 studies that met the inclusion criteria. Of the cohort studies, 26 (92.8%) demonstrated a significant association between autoimmune diseases and increased cardiovascular risk. The major mechanisms include chronic inflammation, endothelial dysfunction, oxidative stress, and immune cell dysregulation. Essential biological components, including T cells, B cells, and neutrophils, were identified as contributors to atherosclerotic processes through cytokine secretion, expression of adhesion molecules, and thrombogenic activity. In contrast, two studies (7.1%) found no statistically significant association. In conclusion, autoimmune diseases significantly increase cardiovascular risk through complicated immunological mechanisms. Comprehending these pathways could influence future therapeutic approaches to reduce cardiovascular complications in affected patients.

26 March 2026 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
Kiana MohammadianKiana Mohammadian
Kiana Mohammadian
TKTahereh Kalantari
Tahereh Kalantari
RERasoul Ebrahimi
Rasoul Ebrahimi
NNNahid Nasiri
Nahid Nasiri
PAParisa Alipour
Parisa Alipour
ABAfshin Borhani-Haghighi
Afshin Borhani-Haghighi
Introduction: Inflammatory and coagulation pathways are crucial in the pathogenesis and clinical progression of ischemic stroke. The objective of this study was to evaluate serum concentrations of interleukin-2 (IL-2) and interleukin-10 (IL-10), as well as the gene expression of tissue factor (TF) in peripheral blood mononuclear cells (PBMCs), and to examine their correlations with stroke severity and clinical outcomes. materials and methods: In a cross-sectional design, we enrolled 148 patients with ischemic stroke and 30 age- and sex-matched healthy controls. Serum concentrations of IL-2 and IL-10 were quantified using ELISA, and TF gene expression in PBMCs was evaluated by real-time PCR. Stroke severity was assessed using the NIH Stroke Scale (NIHSS), and correlations with clinical variables were analyzed. Materials and Methods: We enrolled 148 patients with ischemic stroke and 30 healthy controls matched for age and sex in a cross-sectional design. We used ELISA to measure the levels of IL-2 and IL-10 in serum and real-time PCR to look at TF gene expression in PBMCs. The NIH Stroke Scale (NIHSS) was used to measure the severity of strokes, and the results were compared to clinical variables. results: Patients with severe stroke exhibited significantly reduced levels of IL-2 and IL-10 (p < 0.001), and markedly increased TF [removed]p < 0.001), compared to both mild stroke and control groups. TF levels demonstrated strong diagnostic accuracy for distinguishing stroke severity (AUC = 0.960, p < 0.0001). IL-2 and TF were inversely correlated in severe cases (p = 0.036). However, none of the biomarkers independently predicted survival outcomes. Results: Patients with severe stroke showed significantly lower levels of IL-2 and IL-10 (p < 0.001), and TF expression in PBMCs was significantly higher in both mild and severe stroke groups compared to controls (p <0.001). There was no statistically significant difference between the mild and severe groups (p = 0.213). In severe cases, IL-2 and TF were negatively correlated (p = 0.036). Nonetheless, none of the biomarkers independently forecasted survival outcomes. discussion: The findings indicate a dysregulated immune-coagulation axis in severe ischemic stroke. Reduced IL-2 and IL-10 levels may reflect impaired regulatory T-cell activity and anti-inflammatory control, leading to monocyte activation and increased TF expression. This interplay likely exacerbates thromboinflammatory cascades, contributing to greater neurological damage. These alterations, while not predictive of survival, provide mechanistic insights into stroke pathophysiology and open avenues for targeted immunomodulatory therapy. Discussion: The results show that the immune-coagulation axis is not working properly in severe ischemic stroke. Lower levels of IL-2 and IL-10 may indicate that regulatory T-cells aren't working properly and that anti-inflammatory control isn't working, which can cause monocytes to become active and TF levels to rise. This interaction probably makes thromboinflammatory cascades worse, which leads to more damage to the nervous system. These changes, even though they don't predict survival, give us a better understanding of how strokes work and open up new possibilities for targeted immunomodulatory therapy. Conclusion: The changes in IL-2, IL-10, and TF expression indicate a coordinated disruption of immune and thrombotic pathways in individuals with severe ischemic stroke. Although not prognostic of mortality, these biomarkers may indicate disease severity and represent potential targets for future therapeutic interventions. Longitudinal studies are necessary to validate their prognostic significance and investigate their incorporation into clinical decision-making algorithms for stroke.

11 August 2026 in Cancer Reports
Verified
Journal Article
Open access
MKMehdi Karimi
Mehdi Karimi
FHFarnaz Hooshmand
Farnaz Hooshmand
Kiana MohammadianKiana Mohammadian
Kiana Mohammadian
SPSeyed Morteza Ali Pourfaraji
Seyed Morteza Ali Pourfaraji
MMMasoud Mortezazadeh
Masoud Mortezazadeh
Background and Aim: Lung cancer remains one of the leading causes of cancer‐related mortality worldwide. Type 2 diabetes mellitus (T2DM), the most prevalent endocrine disorder, is commonly managed with Metformin, an antidiabetic medication that has demonstrated potential anticancer properties. This meta‐analysis aimed to discover the association between Metformin use and the risk of lung cancer in patients with T2DM. Methods: A comprehensive search of online databases was conducted up to January 1, 2026, to identify relevant observational studies. After screening, appropriate data were extracted. Meta‐analyses utilized the most fully adjusted hazard ratio (HR) with corresponding 95% confidence intervals (CI) as the effect measures. All statistical analyses were performed using R Statistical Software. Results: The pooled analysis of 29 observational studies showed a significant reduction in lung cancer risk among Metformin users compared with nonusers (HR: 0.85, 95% CI: [0.77–0.94], p = 0.002). Subgroup analyses revealed significant associations in cohort studies (HR: 0.79, 95% CI: [0.70–0.89], p < 0.01) and in studies conducted in Asia (HR: 0.82, 95% CI: [0.68–0.99], p = 0.04). Extended Metformin use (> 3 years) was associated with a significant reduction in lung cancer risk (HR: 0.87, 95% CI: [0.79–0.95]; p < 0.01), whereas no significant effect was observed for shorter durations. Conclusion: This meta‐analysis indicated a potential protective effect of Metformin use in individuals with T2DM against lung cancer, with a significant risk reduction observed, particularly among long‐term users and in Asian populations. The significant associations identified in cohort studies and in extended‐duration use underscore metformin's promise in lung cancer prevention.